Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI expands its global network to India
PHI has entered a business relationship with Medi Analytika India Pvt. Ltd. This new distributor will represent PHI in the large and growing Indian market and manage the full sales process and customer relations for the HoloMonitor® product portfolio.
PHI Focuses on Biomanufacturing — Appoints New CEO and Chairman
The Board of Directors of PHI has appointed the company’s CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board.
PHI Is Opening A New Development Office In The US
As a result of the newly created alliance for advancing cell-based biomanufacturing which was recently communicated, PHI is taking the next step in its investment into regenerative medicine by opening an office in the Innovation Quarter in Winston-Salem.
PHI, SAS, QIAGEN and BioSpherix form Alliance to Advance Cell-based Biomanufacturing
In association with the Wake Forest Institute for Regenerative Medicine, PHI, BioSpherix, analytics leader SAS and QIAGEN have created a technology development alliance to create the AI-based process control tools needed for automated biomanufacturing.
Wake Forest Institute for Regenerative Medicine Welcomes PHI
PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.
Synthetic antibody patent awarded to PHI by Japan
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
HoloMonitor Fluorescence Now at Novo Nordisk
PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.